Worg Pharmaceuticals Secures Major Financing for Allergy and Autoimmune Disease Therapies
Worg Pharmaceuticals (Zhejiang) Co., Ltd., a China-based biopharmaceutical company specializing in the development of immunotherapies...
Abbott Laboratories Expands Global Diabetes Care with New Kilkenny Facility
Abbott Laboratories (NYSE: ABT), a leading US healthcare company, has announced the opening of its...
AbbVie’s Elahere Receives EC Approval for FRα-Positive Ovarian Cancer Treatment
US-based AbbVie (NYSE: ABBV) has announced the European Commission (EC) approval for its antibody drug...
Rona Therapeutics’ RN0191 Showcases Positive Phase I Results at AHA Scientific Sessions
Shanghai-based nucleic acid drug developer Rona Therapeutics has announced the presentation of positive Phase I...
Eli Lilly’s Tirzepatide Meets Primary Endpoints in Phase III SUMMIT Heart Failure Study
Eli Lilly and Company (NYSE: LLY), a leading US pharmaceutical corporation, has announced positive results...
Zai Lab Ltd Announces Secondary Public Offering Worth $230 Million
Zai Lab Ltd (ZLAB; NASDAQ: ZLAB; HKG: 9688), a leading biopharmaceutical company, is set to...
AstraZeneca’s Tagrisso Receives Positive CHMP Opinion for EGFR-Mutated NSCLC
AstraZeneca (AZ, NASDAQ: AZN), a leading UK pharmaceutical company, has announced that the Committee for...
Everest Medicines’ Nefecon Receives Full Approval from South Korea’s MFDS for IgAN Treatment
China-based Everest Medicines (HKG: 1952) has announced that it has received full approval from the...
Eli Lilly’s Muvalaplin Demonstrates Potent Lp(a) Reduction in Phase II Study
Eli Lilly & Co. (NYSE: LLY), a leading US pharmaceutical company, has announced positive results...
Sunshine Guojian Pharmaceutical’s SSGJ-608 Files for NMPA Approval in Plaque Psoriasis
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd, (SHA: 688336) a subsidiary of 3SBio Inc. (HKG: 1530),...
Huahui Health’s Libevitug Earns FDA Breakthrough Designation for Chronic Hepatitis Delta Virus
Beijing-based biotech company Huahui Health, specializing in viral hepatitis, hepatology, and oncology, has announced that...
Xeltis AG Enrolls First Patient in US Pivotal Trial for aXess with FDA BTD Status
Holland-based Xeltis AG has announced the enrollment of the first patient in a US-staged pivotal...
Shanghai Leadingtac Pharmaceutical Secures $13.81 Million in Series A Financing
Shanghai Leadingtac Pharmaceutical Co., Ltd., a China-based small molecule drug developer, has announced the successful...
Huadong Medicine’s DR10624 Receives NMPA Approval for MAFLD and MASH Clinical Trials
China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced that it has received approval from...
NMPA’s CDE Issues Guidelines for Leveraging Real-World Data in Drug Regulation
The Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) has released...
Biosion Secures Licensing Deal with Aclaris Therapeutics for Global Rights to BSI-045B and BSI-502
Biosion, a clinical stage biotech company with operations in Delaware, US, and China, has entered...
Ratio Therapeutics Partners with Novartis on SSTR2 Radiotherapeutic for Cancer
US-based Ratio Therapeutics Inc. has entered into a global exclusive licensing and cooperation agreement with...
Huadong Medicine’s HDM1005 Receives FDA Approval for MASH Clinical Study
Huadong Medicine Co., Ltd (SHE: 000963), a China-based pharmaceutical company, has announced that it has...
TenNor Therapeutics’ Rifasutenizol Shows High Eradication Rate in H. pylori Phase III Study
China-based TenNor Therapeutics has announced positive results from its Phase III clinical study for rifasutenizol...
Beijing Wantai Receives NMPA Clearance for Nine-Valent HPV Vaccine Targeting Male Population
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd (SHA: 603392), a leading Chinese pharmaceutical company, has...